Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Descartes-25 in Relapsed/Refractory Multiple Myeloma
NCT05113342Phase 1Terminated
- Sponsor
- Cartesian Therapeutics
- Start
- Nov 2021
- Primary completion
- May 2023
- Modality
- Gene Editing, Gene Silencing, Stem Cell Therapies
- Countries
- 2
01
Overview
Phase 1, open-label trial of DESCARTES-25 in multiple myeloma (MM) (4 arms), sponsored by Cartesian Therapeutics. Primary endpoint: Maximum Tolerated Dose at 1 year. Started Nov 2021; status: terminated.
02
Drugs
DESCARTES-25
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05113342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05113342.